findmyKOL

Hedy Kindler, MD

Enriched profile

Associate Dean for Clinical Science Research, Human Subjects, and Professor of Medicine (Section of Hematology/Oncology), University of Chicago Pritzker School of Medicine · University of Chicago

ORCID↗NPI↗
✓ Full profile
Region🇺🇸 Chicago, IL · Midwest · United StatesSpecialtyHematology / OncologyFocusOccupational and environmental lung diseases+4
Active KOLfindmyKOL type: EliteLatest publication2025Online presenceNone verifiedPayments2021–2024NIH funding2000–2026

Hedy Kindler is Associate Dean for Clinical Science Research, Human Subjects, and Professor of Medicine (Section of Hematology/Oncology), University of Chicago Pritzker School of Medicine at University of Chicago. OpenAlex indexes 662 publications with 39,455 citations (h-index 91); ClinicalTrials.gov lists 35 registered studies with this person as an investigator. By OpenAlex citation count, this profile ranks in the top 5% of Hematology / Oncology profiles in the findmyKOL directory.

Data verified 14 Aug 2026

Overview

Updated 13 Oct 2026

Hedy Kindler is Associate Dean for Clinical Science Research, Human Subjects, and Professor of Medicine (Section of Hematology/Oncology), University of Chicago Pritzker School of Medicine. The public record shows 662 publications with 39,455 citations (h-index 91), centered on Occupational and environmental lung diseases, Pancreatic and Hepatic Oncology Research, Pleural and Pulmonary Diseases. It also documents an investigator role on 35 registered clinical trials, industry payments reported by 7 companies, 6 NIH-funded awards (2000–2026).

  • Most recent indexed publication: 2025 · JCO oncology practice
  • Top research focus: Occupational and environmental lung diseases
  • 35 registered trials on ClinicalTrials.gov
  • Open Payments reporting from 7 companies

Generated from the cited public record · current as of 13 Oct 2026. Every fact links its source below.

Indications focus

from trials led + research topics
Mesothelioma13 trialsPancreatic Cancer9 trialsColorectal Cancer7 trialsRectal Neoplasms7 trialsMesothelioma, Malignant7 trialsSarcoma5 trialsComa5 trialsBladder / Urothelial Cancer3 trialsHepatobiliary Cancer3 trialsLiver Neoplasms3 trialsGallbladder Neoplasms3 trialsBile Duct Neoplasms3 trialsGastroesophageal Cancer2 trialsStomach Neoplasms2 trialsColonic Neoplasms2 trialsCholangiocarcinoma2 trialsGastrointestinal Stromal Tumors1 trialEsophageal Neoplasms1 trialAdenocarcinoma, Mucinous1 trialProstate Cancer1 trialOvarian / Gynecologic Cancer1 trialLymphoma1 trialEndometrial Neoplasms1 trialLymphoma, T-Cell1 trialProstatic Neoplasms, Castration-Resistant1 trial

Research focus

OpenAlex concept fingerprint
Occupational and environmental lung diseasesPancreatic and Hepatic Oncology ResearchPleural and Pulmonary DiseasesCancer Genomics and DiagnosticsCancer Research and Treatments

Drugs & molecules

across trials, industry payments and publications
Lynparzageneric · OlaparibClinical trials—Industry payments1Publications3PembrolizumabClinical trials1Industry payments—Publications1Qinlockgeneric · RipretinibClinical trials—Industry payments2Publications—VopimetostatClinical trials1Industry payments—Publications—

Works with

trial sponsors and companies reporting payments
University of ChicagoClinical trials16Industry payments—National Cancer Institute (NCI)Clinical trials14Industry payments—Amgen Inc.Clinical trials—Industry payments2Deciphera Pharmaceuticals Inc.Clinical trials—Industry payments2Seagen Inc.Clinical trials—Industry payments2Alliance for Clinical Trials in OncologyClinical trials1Industry payments—AstraZeneca Pharmaceuticals LPClinical trials—Industry payments1AstraZeneca UK LimitedClinical trials—Industry payments1M.D. Anderson Cancer CenterClinical trials1Industry payments—Novartis PharmaceuticalsClinical trials1Industry payments—Novocure Inc.Clinical trials—Industry payments1Sanofi Us Services Inc.Clinical trials—Industry payments1Tango Therapeutics, Inc.Clinical trials1Industry payments—Taxolog Inc.Clinical trials1Industry payments—

Scholarship

indexed output and impact (OpenAlex)
View publications ↓
662publications

Distinct works indexed by OpenAlex, matched via ORCID; 13 in PubMed.

39,455citations

Total citations across indexed works.

91h-index

Hirsch index (OpenAlex). i10-index 319.

Clinical & industry

trials, payments and federal funding
35clinical trials

Investigator role on registered studies.

View trials ↓
7companies · 2021–2024

Companies reporting payments to CMS. Facts, not judgments.

View payments ↓
6NIH grants · 2000–2026

Federally funded research awards.

View funding ↓

Public positions

sourced statements on record

Contact

The practice address and phone this provider lists in the federal NPPES (CMS) registry.

Practice address

Telephone

Practice address and telephone from the federal NPPES registry.

Sign in to view contact details →

Clinical trials

Updated 13 Oct 2026

Listed as an investigator on 35 registered studies on ClinicalTrials.gov. The most recent:

All 35 trial records: search, sort and filter.Explore →

Industry payments

Updated 13 Oct 2026

7 companies reported payments to CMS in program years 2021–2024. These are public disclosures, not judgments. The latest:

All 7 payment records: search, sort and filter.Explore →
View the CMS Open Payments record ↗

Medicare prescribing footprint (2024)

The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.

  • Blood & clotting

    35.1%
    Factor Xa inhibitor35.1%
    Eliquis100%
    Part D<11 patients

  • Cancer & immunology

    25.8%
    Kinase inhibitor25.8%
    Imatinib Mesylate100%
    Part D<11 patients

  • Sensory organs

    19.6%
    Corticosteroid19.6%
    Dexamethasone100%
    Part D<11 patients
All 4 therapeutic areas: search, sort and filter.Explore →
Where care is delivered (Part B)100% facility · 0% office

Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.

NIH funding

Updated 13 Oct 2026

6 NIH research awards on record, funded 2000–2026 per NIH RePORTER. The latest:

All 33 award records: search, sort and filter.Explore →

Congress activity

Updated 13 Oct 2026

163 congress contributions (2004–2025) across AACR, ASCO, ASTRO, ESMO per OpenAlex. The most recent:

All 163 congress records: search, sort and filter.Explore →

Published abstracts are attributed via the same ORCID-disambiguated authorship as publications, so each is DOI-verified. Podium roles (invited talks, session chairs) and oral/poster type are added as program data is confirmed.

Publications

Updated 13 Oct 2026

Their five most recent publications, matched to their ORCID record and linked to PubMed.

All 13 publications: search, sort and filter.Explore →

Most-cited works

by citation count (OpenAlex)
  1. 01
    The IASLC Lung Cancer Staging Project: Proposals for Revision of the TNM Stage Groupings in the Forthcoming (Eighth) Edition of the TNM Classification for Lung Cancer
    Article4,685 citations2016
    doi.org ↗
  2. 02
    Association of tumour mutational burden with outcomes in patients with advanced solid tumours treated with pembrolizumab: prospective biomarker analysis of the multicohort, open-label, phase 2 KEYNOTE-158 study
    Article2,526 citations2020
    doi.org ↗
  3. 03
    Maintenance Olaparib for Germline <i>BRCA</i> -Mutated Metastatic Pancreatic Cancer
    Article2,231 citations2019
    doi.org ↗
  4. 04
    Gemcitabine Plus Bevacizumab Compared With Gemcitabine Plus Placebo in Patients With Advanced Pancreatic Cancer: Phase III Trial of the Cancer and Leukemia Group B (CALGB 80303)
    Article844 citations2010
    doi.org ↗
  5. 05
    The IASLC Lung Cancer Staging Project: Proposals for Coding T Categories for Subsolid Nodules and Assessment of Tumor Size in Part-Solid Tumors in the Forthcoming Eighth Edition of the TNM Classification of Lung Cancer
    Article730 citations2016
    doi.org ↗
All 662 cited works: search, sort and filter.Explore →

Network

Updated 13 Oct 2026

The people this person publishes with most, by number of co-authored papers. Names link to their own profile when we have one.

Everett E. Vokes58Blasé N. Polite57Raffit Hassan53Valerie W. Rusch51Harvey I. Pass49Theodore Karrison48Aliya N. Husain48Daniel V.T. Catenacci47Anna K. Nowak45Mark J. Ratain44Samuel G. Armato43Kiran K. Turaga41Eileen M. O’Reilly41David C. Rice41Alan P. Venook39Marjorie G. Zauderer38Françoise Galateau-Sallé38Talia Golan38Donna Niedzwiecki37Seiki Hasegawa36Charles S. Fuchs36Mitchell C. Posner36William D. Travis34Kevin K. Roggin34Takashi Nakano34Lee M. Krug34Anne S. Tsao33Thierry Jahan33Gershon Y. Locker32Dirk G. Brockstedt30Tanguy Y. Seiwert29Aimee Murphy29Kouros Owzar29Federico Innocenti28Anish Thomas28Chan C. Whiting28Nitya Nair27Ravi Salgia26Samantha Lomnicki26Amanda Enstrom26

Background & recognition

Updated 13 Oct 2026

Credentials, appointments and honors, newest first, each linked to the public source it came from.

Education

degrees and training on record
  • MD

    State University of New York at Buffalo (SUNY Buffalo)

    verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →medicine.uchicago.edu ↗
  • Internal Medicine residency

    UCLA and Montefiore Medical Center

    verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →medicine.uchicago.edu ↗
  • Fellowship in Hematology/Oncology

    Memorial Sloan Kettering Cancer Center

    verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →medicine.uchicago.edu ↗
  • Board Certified

    Medical Oncology

    verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →uchicagomedicine.org ↗

Editorial & leadership roles

journal and society appointments
  • Associate Vice Chair for Clinical Research

    Department of Medicine, University of Chicago

    2019
    verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →medicine.uchicago.edu ↗
  • Director

    Multidisciplinary Mesothelioma Program, University of Chicago Medicine

    verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →uchicagomedicine.org ↗
  • Medical Director

    Gastrointestinal Oncology, University of Chicago Medicine

    provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →mesothelioma-lung-cancer.org ↗
  • Chair

    Clinical Trials Review Committee, University of Chicago Comprehensive Cancer Center

    verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →medicine.uchicago.edu ↗
  • Lead Principal Investigator

    NCI National Clinical Trials Network grant (University of Chicago)

    provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →medicine.uchicago.edu ↗

Awards & honors

honors on the public record

Secondary affiliations

appointments beyond the home institution
  • Executive Committee member

    Alliance for Clinical Trials in Oncology

    provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →medicine.uchicago.edu ↗
  • Member

    Mesothelioma Task Force, International Association for the Study of Lung Cancer (IASLC)

    provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →medicine.uchicago.edu ↗
  • Member

    Science Advisory Board, Mesothelioma Applied Research Foundation / Mesothelioma Foundation

    provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →uchicagomedicine.org ↗
  • Member

    NCI Pancreatic Cancer Task Force

    provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →uchicagomedicine.org ↗

Media & interviews

press, podcasts and appearances

Every item links to where we found it. verified means we've confirmed it in more than one place; provisional means we found it and are still confirming.

Similar KOLs

Other experts from the same institution or the same specialty.